EMA finds additional risk in J&J COVID vaccine

Friday, 01. October 2021 13:35

The European Medicines Agency stated on Friday that there is a potential risk of developing immune thrombocytopenia (ITP), excessive bruising and bleeding, and venous thromboembolism (VTE), deep vein blood clots, after getting the Johnson and Johnson coronavirus vaccine.

The regulator noted that excessive bruising may occur within the first four weeks of receiving the Johnson and Johnson vaccine, especially in people with a history of the disease and low blood platelets. Meanwhile, for deep vein blood clots, the watchdog concluded that symptoms developed rarely, but are a risk for those with increased risk factors for blood clots.

Related Links: Johnson & Johnson
Breaking the News / OL